Peptide bioavailability is limited by rapid enzymatic degradation from serum peptidases, proteases in the gastrointestinal tract, and intracellular proteolytic pathways. Native peptides demonstrate half-lives of minutes to hours. Researchers have developed multiple strategies to enhance peptide stability, including sequence modifications, chemical synthesis approaches, and formulation techniques, extending bioavailability from minutes to days or weeks.
Peptidase Classes and Degradation Pathways
Peptide degradation occurs through exopeptidases (cleaving from peptide termini), endopeptidases (cleaving internal bonds), and specific proteases targeting particular amino acid sequences. Serum proteases including thrombin, elastase, and various metalloproteases rapidly degrade unmodified peptides. The gastrointestinal tract contains numerous peptidases including pepsin (stomach), pancreatic enzymes (chymotrypsin, trypsin), and brush border peptidases (intestinal epithelial cells). Intracellularly, proteasomal and lysosomal proteolysis degrades peptides delivered via endocytosis.
Sequence Modifications for Enhanced Stability
Non-standard amino acids reduce peptidase recognition and enhance stability. D-amino acids (mirror images of L-amino acids) are resistant to many L-amino acid-specific peptidases. SS-31 contains D-arginine at the N-terminus, conferring resistance to arginine-specific peptidases. N-methylation of backbone atoms and side chains slows protease cleavage. Proline-rich sequences naturally resist degradation, as evidenced by BPC-157’s exceptional stability resulting from multiple proline residues positioned strategically throughout the sequence. Cyclization of peptide backbones creates cyclic peptides resistant to exopeptidase cleavage.
Formulation and Delivery Strategies
Peptide encapsulation in nanoparticles, liposomes, or microspheres protects from enzymatic degradation while enabling targeted delivery. Pegylation (attachment of polyethylene glycol polymers) increases peptide half-life by reducing kidney filtration and providing conformational shielding from peptidases. Combination approaches employing peptidase inhibitors (aprotinin, protease inhibitor cocktails) with peptide formulations extend biological half-life. Research continues optimizing delivery vehicles balancing peptide protection, cellular uptake, and cost-effectiveness.
References
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010). Synthetic therapeutic peptides: science and market. Drug Discovery Today, 15(1-2), 40-56. PMID: 20116662
Otvos, L., & Wade, J. D. (2014). Current challenges in peptide-based drug discovery. Frontiers in Chemistry, 2, 62. PMID: 25101284
Zorzi, A., Deyle, K., & Heinis, C. (2017). Cyclic peptide therapeutics: past, present, and future. Current Opinion in Chemical Biology, 38, 24-29. PMID: 28314154
